Back to results
US 2023/0406942 A1Published application
Igf1r antibodies
AssigneeHorizon Therapeutics Ireland DAC
InventorsChristopher Davidson WARD, Martin Jack BORROK, III
Life of this patent
Estimating the term…
Abstract
Described herein are antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1.
Claims37
An antibody or antigen binding fragment thereof that binds insulin like growth factor 1 receptor (IGF1R), wherein the antibody or antigen binding fragment thereof comprises:
- a. an immunoglobulin heavy chain CDR1 (HCDR1) comprising the amino acid sequence SX1GMH, wherein X1 is H, Y, A, or T;
- b. an immunoglobulin heavy chain CDR2 (HCDR2) comprising the amino acid sequence X1IX2X3DX4SX5TYYADSVRG, wherein X1 is I, T, or Y, X2 is W, N, or A, X3 is F, H, A, or G, X4 is G or A, X5 is S or T;
- c. an immunoglobulin heavy chain CDR3 (HCDR3) comprising the amino acid sequence ELX1RRYFDL, wherein X1 is G or N;
- d. an immunoglobulin light chain CDR1 (LCDR1) comprising the amino acid sequence RASQSVSSX1LA, wherein X1 is Y, A, or T;
- e. an immunoglobulin light chain CDR2 (LCDR2) comprising the amino acid sequence DASKRAT;
- and
- f. an immunoglobulin light chain CDR3 (LCDR3) comprising the amino acid sequence QQRX1KX2PPWT, wherein X1 is S or G, X2 is Y or W;
- wherein the antibody or antigen binding fragment thereof does not comprise an immunoglobulin heavy chain variable region identical to SEQ ID NO:
- 1 and/or an immunoglobulin light chain variable region identical to SEQ ID NO:
- 2.
7 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.